Shukra Pharmaceuticals Limited
BSE: SHUKRAPHAR · Pharmaceuticals
Snapshot
Unlock Shukra Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shukra Pharmaceuticals Ltd. is an Ahmedabad-based company engaged in the manufacturing and marketing of a diverse range of pharmaceutical products. Its extensive portfolio encompasses various therapeutic categories, including antibiotics, anti-virals, analgesics, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a broad spectrum of pharmaceutical formulations. It operates as a manufacturer and marketer, distributing its medicinal products across diverse therapeutic segments.
- Incorporation Date:March 4, 1993
Growth Outlook
Growth is expected to be driven by the expansion of its wide-ranging pharmaceutical product portfolio and the continued penetration of both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and other raw materials can significantly impact production costs and profitability.
- Geopolitical and Export Risks. Operating in international markets exposes the company to currency fluctuations, trade barriers, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Shukra Pharmaceuticals Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Shukra Pharmaceuticals LimitedSHUKRAPHAR | ₹2,283 Cr | — | — | — | 51.0% | — | — | +83.1% |
Windlas BiotechWINDLAS | ₹2,377 Cr | 35.61 | 19.64 | 18.5% | 13.0% | 12.2% | 16.8% | +14.5% |
Panacea BiotecPANACEABIO | ₹2,335 Cr | -328.66 | 130.32 | 10.3% | 2.6% | -1.1% | -0.4% | -6.4% |
Sai Parenterals LimitedSAIPARENT | ₹2,295 Cr | — | — | — | 10.0% | — | — | — |
Venus RemediesVENUSREM | ₹2,265 Cr | 19.50 | 12.59 | 20.9% | 21.9% | 19.0% | 23.9% | +265.3% |
Sakar HealthcareSAKAR | ₹2,256 Cr | 62.59 | 28.58 | 43.8% | 29.7% | 11.8% | 15.6% | +197.4% |
As of Mar 2026
Financials
Shukra Pharmaceuticals Limited
BSE: SHUKRAPHAR · Pharmaceuticals
Snapshot
Unlock Shukra Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shukra Pharmaceuticals Ltd. is an Ahmedabad-based company engaged in the manufacturing and marketing of a diverse range of pharmaceutical products. Its extensive portfolio encompasses various therapeutic categories, including antibiotics, anti-virals, analgesics, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a broad spectrum of pharmaceutical formulations. It operates as a manufacturer and marketer, distributing its medicinal products across diverse therapeutic segments.
- Incorporation Date:March 4, 1993
Growth Outlook
Growth is expected to be driven by the expansion of its wide-ranging pharmaceutical product portfolio and the continued penetration of both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and other raw materials can significantly impact production costs and profitability.
- Geopolitical and Export Risks. Operating in international markets exposes the company to currency fluctuations, trade barriers, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Shukra Pharmaceuticals Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026